Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Rare Diseases Congress-2018

About Conference

About Conference

With the success from the previous Rare Diseases Congress-2017, Conference series LLC takes a lot of privilege in inviting all the participants from all over the world to attend “4th World Congress on Rare Diseases and Orphan Drugs, will be held during June 11-12, 2018 in Dublin, Ireland which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions related to Rare Diseases and Orphan Drugs. It serve as a bridge between researchers from academia and health care centres enhanced by its well organized scientific sessions, plenary lectures, poster presentations, world class exhibitions, diverse symposiums, highly enriched workshops and B2B meetings.

ConferenceSeries Ltd Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Rare Diseases Congress-2017 conduct presentations, distributes information, conducts meetings with current and potential scientists, make a splash with new drug developments, There are more than 6,8001 diseases classified as "rare". While individually these entities are uncommon, as a group they are an important cause of chronic illness, disability and premature death in both children and adults. Rare Diseases meeting the academic and long-term research developments can be discussed enabling a comparison between different theories, concepts and approaches

Target Audience:


Infectious Diseases Specialists



Health Care Professionals







Training Institutes

Pharmaceutical Companies

Rare Diseases Associations

Why to Attend?

Rare Diseases and Orphan Drugs conference represents serious uncommon/ unrelated complications that have devastating impacts on people, public health, and economies. This diseases are responsible for rising healthcare costs, lost productivity, and long-term disability. This conference will feature a global audience of scientific leaders, academia and health care professionals, and Orphan Drugs experts who are going to discuss today’s emerging treatments and diagnostics. By bringing together the Rare Diseases community, presenting the latest developments, and identifying unmet treatment needs, Rare Diseases Congress-2017 hopes to accelerate research and drug development in Rare Diseases, improving patient outcomes. It is designed to provide an educational forum that stimulates clinical, research, government and patient communities to create a coordinated and comprehensive approach for advancing the implementation of research, clinical care, care delivery coordination and other public health interventions critical to improved outcomes in Rare Diseases and Orphan Drugs

For Scientific Sessions please go through the link:

For Abstract Submission please go through the link:


Sessions/ Tracks

Track 1: Neglected Tropical Diseases

Neglected tropical diseases (NTDs) are various clusters of tropical infections that are particularly common in low-income populations in developing regions of continent, Asia, and therefore the Americas. They’re caused by a range of pathogens like viruses, bacteria, protozoa and helminths. Effective management are often achieved once elite public health approaches are combined and delivered domestically. Interventions are target-hunting by the native medicine and therefore the convenience of applicable measures to notice, forestall and management diseases. NTDs impair physical and psychological feature development, contribute to mother and kid ill health and death, and create it tough to farm or earn a living, and limit productivity within the geographic point. As a result, NTDs lure the poor during a cycle of financial condition and sickness.

Track 2: Rare Pulmonary Diseases

Rare respiratory organ diseases cause chronic SOB. The Respiratory matter sometimes develops over the age of fifty years, and might have an effect on each men and girls, and additionally youngsters. Around eightieth of rare diseases are caused by genetic factors. They might even be one a part of a wider condition poignant the entire body or be caused by medication given to treat another condition. Respiratory organ alveolar proteinosis is defined by deposition of surfactant-like material within the alveoli, associate degree is an reaction condition related to autoantibodies against granulocyte-macrophage colony-stimulating issue (GM-CSF). Alveolar opacities and ground-glass attenuation with an alleged ‘crazy paving’ pattern on HRCT are characteristic of the disorder. Several rare diseases also are orphan diseases; but, some rare diseases have received important attention, resulting in comprehensive analysis and succeeding treatments specified they will now not be thought-about orphan

Track 3: Rare Diseases in Neurology

RNDs are immensely underdiagnosed and effective treatment is usually lacking with worldwide effort is critical so as to lift awareness and improve information, aiming for earlier identification and specific analysis programmes to spot sickness mechanisms and result in attainable therapies and also Cooperative efforts made to develop “so-called orphan medication. Neurologists play a key role in recognition of rare diseases and lead on their management. Basic and applied neuroscientists are very important to implement analysis on RNDs pathologic process and treatment. The EAN links these disciplines and is accountable for the promotion info}, information, and analysis on these diseases. Youngsters with Batten sickness become blind, bedridden, and brainsick and die. Batten sickness may be a terminal sickness and lifespan varies reckoning on the sort or variation

Track4: Rare Genetic Diseases

Most people United Nations agency have congenital disease have average-size folks during this state of affairs, the FGFR3 point mutation happen in one parent's egg or gamete before conception. People with congenital disease inherit the condition. The complete sequence of the mouse order is thought. Several human genes also are found in mice and mistreatment mice as a model organism for genetic studies has contributed to our understanding of human sickness. Today, researchers will sequence rate mice with a mutation or deletion of a disease-associated gene. They will do elaborate composition analyses of the mutant mice and learn the way the corresponding sequence could operate in humans. For instance, researchers have developed a mouse model of autosomal dominant disorder, within which the mutant mice carry the enlarged CAG repeat among the Huntington's disease-associated sequence. Most definitely, our collective information of single-gene diseases, with the assistance of databases and reference systems, has the potential to advance our understanding of every kind of human sickness in ways in which so much bigger than imaginary at the time of every individual discovery

Track 5: Scope of Orphan Drugs

 Our methodology is well-suited to orphan medicine and rare diseases. What matters could be a proportional sample of target physicians and patients whose experiences may be generalized to the target universe, even though that universe is little. Patient records/treating MD methodology identifies and quantifies these errors. Our triangulation method permits you to optimize your use of pricey claims / secondary knowledge and increase your ROI Orphan medicine, those medications that square measure generally made in tiny quantities for restricted patient populations, square measure growing in importance worldwide. The given the restricted variety of patients littered with a specific malady. With orphan medicine, or with medicine that require to be stirred to promote quickly, extra police investigation of patients is allowed to be done when the trial, to facilitate obtaining the medicine out there during a timely fashion

Track 6: Rare Diseases of Endocrine System

Although many system disorders—such as polygenic disorder, thyroid malady, and osteoporosis—are among the foremost common and well-known medical conditions, some patients World Health Organization are named associate medical specialist would require treatment for a rare malady. However, in rare cases, a regular symptom profile would possibly indicate the onset of a severe and devastating endocrine malady. If a given condition isn't detected at associate early stage, difficulties will intensify. Clinicians will struggle to seek out root causes and core pathology because the rare endocrine disorder could begin to have an effect on numerous body systems. In some 1/2 folks with this disorder, the malady affects the nerve cells within the brain. It additionally involves the adrenal glands and testicles within the majority of the patients.

Track 7: Rare Diseases of Immune System

Rare diseases thanks to alterations within the system represent a field of bioscience of nice interest that's undergoing continuous expansion; these syndromes have an excellent social and economic impact as a result of they typically have an effect on young or terribly teenagers at the peak of their social activities and relationships. In recent years, abundant data has been noninheritable on pathologic process, diagnosis, and medical care, permitting US to confront these syndromes in an exceedingly a lot of holistic manner. The series editors square measure acknowledged specialists on immune diseases United Nations agency have printed extensively on varied aspects of this branch of medication. immunological disorder disorders impair the immune system’s ability to defend the body against foreign or abnormal cells that invade or attack it (such as bacterium, viruses, fungi, and cancer cells). As a result, uncommon microorganism, viral, or fungous infections or lymphomas or alternative cancers could develop

Track 8: Rare Cardiac Diseases

The most common inborn heart defect related to Eisenmenger syndrome may be a bodily cavity congenital heart defect (VSD) or a "hole within the heart" between the 2 lower chambers of the guts (left ventricle and heart ventricle. This defect permits blood to be due the heart ventricle into the proper ventricle (left-to-right shunt). The shunt causes magnified blood flow into the lungs eventually leading to pneumonic cardiovascular disease that causes progressive harm to the tiny blood vessels in lungs (pulmonary vascular sickness. Eisenmenger syndrome may be a rare progressive heart disease that develops in some people with structural malformations of the guts that are gift from birth (congenital heart defects). The disorder is characterised by magnified force per unit area within the main vessel (pulmonary artery) connecting the guts to the lungs (pulmonary hypertension) and improper blood flow inside the guts.

Track 9: Rare Eye and Ear Diseases

Onset of the illness is mostly a quick episode of inflammatory disease, most typically opening rubor. different inflammatory eye conditions that will occur embrace redness, rubor or redness. These eye conditions cause pain, bodily function (tearing of the eye) and photophobia. The symptoms usually deteriorate more and more among days. whereas the ESR, WBC, and C-reactive protein check could also be abnormal and there could also be symptom or anemia, none of those findings area unit reliable indicators of the illness. A slit-lamp examination is crucial. Recent work has instructed that high-resolution magnetic resonance imaging and antibodies to sensory receptor antigens could also be useful. Immediate treatment for Cogan’s syndrome is with steroids, that scale back the inflammatory response. TNF-alpha is powerful medication agent that has been employed in atiny low range of patients

Track 10: Orphan Drugs Treatment for Rare Diseases

An orphan drug may be a medicative product developed for the treatment of a rare malady. In Europe, a rare malady is outlined as a condition that affects but five per ten, 000 inhabitants, and is fatal or severely debilitative. There square measure over seven,000 renowned rare diseases, which implies that many million individuals square measure affected everywhere the planet – over twenty five million in Europe alone. Today, treatment exists for less than 200–300 diseases. Rare diseases square measure usually genetic, that means that new-borns, children, and young adults usually square measure affected. Physicians might ne'er see a patient with a rare malady. The program has with success enabled the event and promoting of over 600 medicine and life merchandise for rare diseases since 1983. In distinction, The Orphan Grants Program has been accustomed bring quite sixty merchandise

Track 11: Rare Oral Diseases

Researchers targeted on dental, oral and craniofacial manifestations of rare bone diseases mentioned during this report are defects in four key physical processes in bone/tooth formation that function models for the understanding of different diseases within the skeleton and DOC complex: antecedent cell differentiation (fibrous dysplasia), living thing matrix production mineralization and bone biological process. For every condition, the authors highlight responsible mutations within the skeleton and DOC advanced, and coverings.

Track 12: Rare Hepatic Diseases

There are over one hundred totally different varieties of liver diseases that have an effect on men, ladies and youngsters. Cystic malady of the liver is rare and might take many forms. Cysts within the main trunk of the biliary tree are known as choledochal cysts. Cysts that occur within the little branches of gall ducts among the liver are cited as Caroli’s syndrome. The opposite cysts within the liver that don't occur within the biliary tree are cited as polycystic disease. Sometimes, this accumulated gall becomes infected, inflicting abdominal pain and fever. In some patients the cyst are often felt by the doctor examining the abdomen. In most patients the diagnosing are often confirmed by ultrasound or by injecting a radioactive substance which supplies associate in nursing “image” of the abnormal duct. The abnormal channel is removed and a bit of viscus is employed to exchange it

Track 13: Rare Gastrointestinal Diseases

Rare disorder of metallic element metabolism that may either be genetic or non-inheritable, each forms cause the shortcoming to soak up metallic element from the bowel. The dearth of metallic element will cause skin inflammation with a rash (pustular dermatitis) round the mouth and abnormal nails (nail dystrophy). Irritability and emotional disturbances may also occur. The genetic kind is caused by mutations within the SLC39A4 factor associated genetic in a chromosome recessive pattern. The noninheritable kind may end up from diets lacking the acceptable quantity of metallic element. Mutations in a minimum of fourteen genes are notable to cause Bardet-Biedl syndrome and inheritance is sometimes chromosome recessive. Treatment depends on the symptoms gift in everyone. The inner anatomical sphincter unremarkably stays closed to stop the discharge of gas or liquid from the body part, however once the body part fills up with gas or feculent material, a reflex causes it to hospitable permit the movement.

Track 14: Rare Bacterial, Viral and Fungal infections

Infectious rubor is also caused by a broad vary of microorganism, fungal, parasitic, and infective agent agents. Infectious Rubor is overall uncommon given the relative resistance of the muscular structure to infection, as an example, inciting events, as well as trauma, surgery, or the presence of foreign bodies or devitalized tissue, area unit usually gift in cases of microorganism rubor. Parasitic rubor is most typically a results of myositis or cystericercosis, however different protozoa or helminths is also concerned. A parasitic reason behind rubor is recommended by the travel history and presence of symptom. Viruses could cause diffuse muscle involvement with clinical manifestations, like benign acute rubor (most normally owing to respiratory disease virus). Less normally, different viruses like HIV, herpes simplex, and also the West Nile virus will cause infectious disease. Most often, once a deadly disease is guilty, the infection is typically fairly delicate, and will even escape while not treatment.

Track 15: Rare Diseases of Genitourinary System

Urofacial syndrome (UFS), conjointly disorder characterised by associate uncommon countenance and disorder of the tract (uro pathy) once the bladder tries to empty the outlet closes that means that the pee goes back towards the kidneys instead of out of the body. The abnormalities related to this condition could cause short stature. Loss of bone (osteolysis) within the hands and feet could be a characteristic feature of this condition. Alternative options of AOD could embody distinctive facial expression, loose joints, dental issues, excess hair, repeated infections, heart defects, and excretory organ abnormalities. Prompt designation and treatment will scale back or probably stop severe, irreversible bladder and excretory organ harm referred to as pathology with peculiar countenance, is a particularly with rare diseases

Track 16: Rare Diseases in Nephrology

Some rare, or less common, diseases will cause urinary organ injury that ends up in chronic uropathy and kidney disease. a number of these rare diseases embody AL port syndrome, malady, Goodpasture syndrome, and Wegener’s granulomatosis. Many of those diseases occur within the context of inflammation and disease (eg, Goodpasture syndrome). Several rare varieties of inflammation may also cause major urinary organ issues designation begins with a physical communicating and taking an anamnesis. Sickness symptoms vary, however will embody swelling from water retention, blood within the excrement, urinary organ pain, anemia, elevated pressure level, urinary organ stones, and solution imbalances. Basic blood and excrement tests square measure sometimes enough to diagnose the existence of urinary organ issues, however typically not the precise condition. Imaging tests like ultrasounds or CT scans will facilitate aid in designation, as will a urinary organ diagnostic test to spot the precise sickness method

Track 17: Rare Skin Diseases

Poor understanding of the explanation of the planned indication thanks to few data-based studies finding out malady progression, heterogeneous patient populations with variable phenotypes and clinical courses, geographic dispersion of patients and investigators, restrictive uncertainties, and lack of previous clinical studies to determine a template for study execution, In rare malady trials, the necessity to recruit and retain patients whereas adhering to exceptional standards of care influences each call. The protocol should account for the vulnerability of the patient population and address moral concerns, significantly if the study style mandates ending of current medical aid thought-about essential for patient support. Eligibility criteria invariably influence the quantity of accessible subjects, and if unnaturally forced, scale back the chance of creating clinical trials info from that proof of effectiveness and safety

Track 18: Clinical Research on Orphan Drugs

Creating a pharmaceutical development program for the treatment of a rare malady will, however, persuade be a monumental task. Poor understanding of the explanation of the planned indication as a result of few empirical studies learning malady progression, heterogeneous patient populations with variable phenotypes and clinical courses, geographic dispersion of patients and investigators, regulative uncertainties, and lack of previous clinical studies to determine a template for study execution, In rare malady trials, the necessity to recruit and retain patients whereas adhering to exceptional standards of care influences each call. The protocol should account for the vulnerability of the patient population and address moral issues, notably if the study style mandates discontinuance of current medical aid thought of essential for patient support. Eligibility criteria perpetually influence the amount of obtainable subjects, and if by artificial means strained, scale back the chance of building clinical trials information from that proof of effectualness and safety

Track 19: Rare Morphological Diseases

The extent to that biological process changes have compact the makeup relationships among human diseases remains unclear. During this work, we have a tendency to report that phenotypically similar maladys are connected by the biological process constraints on human disease genes. While many genes are concerned within the pathological process of the various types of osteoporosis, the CLCN7 and TCIRG1 genes have drawn the eye of the many researchers as mutations among these genes are related to distinct phenotypes. Knowledge on many distinct morphological patterns of bone in cases of Albers-Schonberg disease are bestowed here alongside the discussion of potential clinical implications. This impairment within the production of pigment results in shrivelled haemoprotein in red blood cells, thereby reducing MCH and MHCH and inflicting hypochromia and blood disease

Track 20: Development of Orphan Products

The Orphan Drug provides orphan standing to medicine and biologics that area unit outlined as those supposed for the safe and effective treatment, designation or interference of rare diseases/disorders that have an effect on fewer than two hundred folks within the U.S., or that have an effect on over two hundred persons however don't seem to be expected to recover the prices of developing and promoting a treatment drug. The goal of the Orphan merchandise Clinical Trials Grants Program (formerly referred to as Orphan merchandise Grants) is to encourage clinical development of merchandise to be used in rare diseases or conditions. Last, the paediatric Medical Device Safety and Improvement Act of 2007 (Public Law 110-85) permits HDE approved devices supposed to be used in paediatric patients or in an exceedingly paediatric population and approved

Track 21: Rare Diseases in Oncology

Rare cancers and diseases still cancers that will be predominant in medically underserved populations. In several cases, the data CCR’s investigators gain from learning and treating rare cancers and connected diseases provides them with insights into the mechanisms that underlie different additional common malignancies. Rare cancers and rare diseases are to deal with challenges and propose solutions to eliminate the hurdles with those patients suffering with rare cancers, researchers, medical professionals. it's meant that the in-depth, knowledge base dialogue of this skilled working party can formulate AN rising agreement on an operating definition of symptom clusters and, specific gaps and opportunities that give a foundation for a transformative strategic blueprint to guide future symptom cluster analysis in rare cancers.

Track 22: Rare Diseases in Anaesthesiology

Anesthesia is changing into safer over the past decades. This method was driven by the event of recent aesthetics and therefore the institution of recent safety ideas. On the opposite hand anesthetists have the benefit of profound pathophysiological information and therefore the competency of translating patient specific conditions into individual perioperative risk. Orphan Anaesthesia is that the publication of physiological condition recommendations for patients laid low with rare diseases with the target of rising patients’ safety. Once it involves the management of rare diseases, there square measure solely spare evidence-based facts and even way less information within the anaesthetic outcome. Physiological condition and Uncommon Diseases brings you up thus far with new data on less unremarkably seen diseases and conditions, together with the most recent proof and management analysis

Track 23: Rare Diseases in Haematology

Rare medicine diseases be several subcategories, together with anemia-type red vegetative cell conditions (eg, erythrocyte sickness, beta monogenic disorder, and Diamond-Blackfan anemia), white vegetative cell dysfunctions related to numerous malignancies platelet-based abnormalities that have an effect on action. Screening newborns for rare blood and alternative diseases is a way to more optimize diagnostic potency. This field, particularly, is marked by speedy technological advances; presently, about 4.1 million infants’ are screened associatenually for an ever-growing list of rare gene-based diseases. They embody the addition and/or removal of blood elements, growth-factor medication, immunological disorder medication, somatic cell and bone marrow transplantation, and gene-based medication. If a condition is related to a nonmalignant neoplasm or a cancerous malignancy, biological agents or therapy could also be used.

Track 24: Orphan Drugs Market Research

Diseases that have low prevalence rates aren't any smaller than ones that have a better incidence. Pharmaceutical agents developed for treating such rare or low-prevalence diseases are spoken as orphan medicine. Countries usually laws crucial the treatment and approach to orphan diseases. Currently, the marketplace for orphan medicine constitutes solely regarding 6 June 1944 of the whole pharmaceutical market. The same factors can facilitate this market succeed double-digit CAGR through the forecast amount of the report. Yet, growth within the market is curtailed to some extent by challenges like finding the required range of patients for clinical trials. The demand for orphan medicine has hyperbolic considerably as a result of surge in prevalence of rare diseases. Additionally, the increase in awareness among the people concerning rare diseases and increase in R&D investment and drug development drive the market growth

Track 25: Rare Gynecological and Obstetrical Diseases

Gestational tissue layer sickness (GTD) may be a rare cluster of diseases that develop within the womb throughout AN abnormal physiological condition. It happens once abnormal cells or tumors grow within the tissues that square measure shaped following conception that may unremarkably surround the embryo and transform the placenta. Acute gonococcal or venereal disease redness might result in the Fitz-Hugh-Curtis syndrome (perihepatitis that causes higher right quadrant pain). Infection might become chronic, characterised by intermittent exacerbations and remissions

Track 26: Pediatric Rare Diseases

Patients with Rare Diseases typically gift with common symptoms that square measure unnoted, treated singly or misdiagnosed, delaying applicable treatment. The Excellence in pediatrics Institute has double surveyed paediatric aid professionals globally and located that solely sixty three known juvenile upset arthritis|autoimmune disorder as a disease that's ordinarily confused with the hallucinogen MPS. Paediatricians and family doctors square measure doubtless to be the primary aid professionals to look at symptoms of Rare Diseases, and it's necessary to assist these front-line clinicians suspect, diagnose, and refer patients notably once Rare Diseases that square measure treatable occur. Prompt treatment reduces mortality yet as morbidity together with irreversible physical and psychological feature harm. The Initiative is about to facilitate front-line clinicians to suspect, diagnose, and refer patients once a rare illness that has the potential for treatment happens.

Track 27: Current Rare diseases Research

Rare diseases represent diseases health professionals square measure usually less intimate because of their infrequent prevalence, as a result of they receive very little focus in medical coaching programs and since they often don't represent a viable marketplace for industrial product, while not specific incentives increasingly being introduced. Analysis into rare diseases (RD) is badly required as several patients still lack a correct designation and most of them square measure left while not effective treatment. It’s additionally wherever consultants are rare yet. So as to translate analysis results into medical specialty and into the selling of orphan medication, it's essential that data, knowledge and samples to spice up analysis be shared internationally. Thus RD classification, knowledge repositories, customary terms of reference and customary ontologies, yet as harmonious regulative needs got to be established at international level.

Track 28: Rare Diseases of Sexual Health

Sexually transmitted diseases (STDs) affecting their harmful consequences with the people, families, and communities. Uncommon sexual conditions, though, place some individuals clearly outside the norm. Most of those conditions area unit rare, however that does not matter abundant to you if you've got one. It will be a large supply of physical and emotional pain, shame and embarrassment. In some cases, it is so tough to modify that the person's entire life revolves around it. Typical sex development needs multiple genes, hormones, and secretion receptors to sex chromosome disorders of sex development (DSD) area unit caused by either disorders of gonad development or disorders

Track 29: Rare Hereditary Diseases

The human ordination is continually exposed to varied sources of desoxyribonucleic acid injury. Ineffective protection from this injury results in genetic instability which might ultimately bring about to corporal unwellness, inflicting mutations. Thus our organism commands variety of extremely preserved and effective mechanisms answerable for desoxyribonucleic acid repair. If these repair mechanisms are defective thanks to germline mutations in relevant genes, rare diseases with desoxyribonucleic acid repair deficiencies will arise. Today, a restricted variety of rare hereditary diseases characterised by genetic defects of desoxyribonucleic acid repair mechanisms is thought, comprising neurological disease telangiectasia, Nijmegen breakage syndrome, Chronic inflammatory disorder of the viscus, involves any region of the GI tract from the mouth to the porta. The swelling and inflammation will go deeply into the liner of the viscus. This may be terribly painful and may cause diarrhoea, abdominal pain, nausea and decreased appetency. The inflammatory method tends to be eccentric and segmental, usually with skip areas

Track 30: Diagnosis and Treatment for Rare Diseases

In one study, Toro et al according eighty nine of patients with Birt-Hogg-Dubé syndrome had pneumonic cysts on CT scans pulmonary cysts and spontaneous pneumothoraces have additionally been progressively according manifestations of Birt-Hogg-Dubé syndrome. Further, the study incontestible pure gold of Birt-Hogg-Dubé syndrome patients and thirty fourth of Birt-Hogg-Dubé syndrome members of the family screened for respiratory organ cysts had a history of spontaneous abnormal condition. However designation is just the primary challenge, with solely five-hitter of rare diseases having even one medical care approved by the Food and Drug Administration (FDA), the number one reason is that pathological process and therefore the underlying biology

Track 31: Clinical Case Studies on Rare Diseases

The clinical presentation, explanation, pathophysiology, and sometimes mysterious nature of rare diseases have fascinated physicians for hundreds of years. Rare diseases offer opportunities to review human physiology and bioscience from distinctive views. Major scientific breakthroughs ensuing from investigation of rare diseases have usually provided insight into a lot of common disorders. The satisfaction of diagnosis a patient with a rare disorder with success is commonly chop-chop countered by the conclusion that the flexibility to know and treat the patient’s condition is restricted by mental object and also the difficulties of finding out the malady. Clinical investigators in rare malady analysis additionally frequently face challenges specific to the study of uncommon disorders. Maybe the foremost frequent downside is that the enlisting of a requisite variety of study subjects for Associate in Nursing data-based cohort or a run. This would like needs the creation of multi-institutional and international collaborations to conduct clinical investigation in rare diseases

Track 32: Imaging of Rare Diseases

More than six thousand rare diseases are detected to this point and that they have an effect on 6-8% of the population that equals two.3-3 million folks in European nation. A number of the rare diseases are already diagnosed in utero, e.g. skeletal dysplasias on imaging or central system diseases on resonance imaging. Our understanding of viscus involvement in FD is restricted as a result of the myocyte storage can't be assessed non-invasively.T1 mapping incontestible glorious discrimination between FD and different causes of LVH, and this property is very suggestive an instantaneous however knotty relationship between T1 signals and abnormal fat storage. Specifically, five hundredth of patients while not LVH has low T1 values, suggesting that T1 is Associate in nursing early malady marker

Track 33: Other Rare Diseases

The field of rare diseases suffers from a deficit of medical and knowledge base. For an extended time, doctors, analysers and policy manufacturers were unaware of rare diseases and till terribly recently there was no real research or public health policy regarding problems associated with the sector. There’s no cure for many rare diseases, however the acceptable treatment and treatment will improve the standard of lifetime of those affected and extend their anticipation. Spectacular progress has already been created surely diseases that show that we have a tendency to should not quit the fight, however on the contrary, continue and intensify efforts within the fields of analysis and social commonality. Those laid low with these diseases all face similar difficulties in their pursue a designation, relevant data and correct direction towards qualified professionals. Specific problems square measure equally raised concerning access to quality health care, overall social and medical support

Market Analysis


We are pleased to announce the 4th World Congress on Rare Diseases and Orphan Drugs, which will present an exciting blend of genetic diseases, Rare Diseases Research, and clinical medicine. We aim to explore new challenges and concepts associated with Rare Diseases and Orphan Drugs Research-edge genomic research translates into clinical care and informs our understanding of the treatment mechanism of rare diseases. Rare Diseases Congress-2017 meeting will focus on the emerging role of non-coding variants in disease, impact health and disease, and the emerging technologies used to understand the sequences of rare diseases genome. We will also include a session on rare disease clinical trials and will debate current ethical issues.

Rare Diseases Congress conference provides an excellent multi-disciplinary forum for clinicians (consultants and trainees), research scientists, bioinformaticians and technology developers, Academicians, Pharmaceutical Research Experts interested in understanding the impact of recent advances in research and Diagnostics and technology on the care of patients with rare diseases.

Importance and Scope

Rare diseases are an important public health issue and a challenge to medical care. Specific legislation to encourage research of rare diseases and development of orphan drugs has been adopted in the United States (US), the European Union (EU), and elsewhere. Some rare conditions are extremely rare, with the number of reported cases in the single or low double digits. Others occur in hundreds, thousands, or tens of thousands of people. Many of the estimated 5,000 to 8,000 rare conditions are genetic or have a genetic component. Others arise from exposure to infectious agents or toxins and, occasionally, from adverse responses to therapeutic interventions. In recent years, much progress has been made in some parts of Asia, including Japan, South Korea, and Taiwan, with the enactment of legislation and accompanying regulation of rare diseases and orphan drugs. China is also actively promoting the regulation of rare diseases and orphan drugs

 As the Rare Diseases Congress-2017 undertakes a range of activities to encourage and support research on rare conditions. The Rare Diseases Clinical Research Network funds consortia to study groups of related rare conditions. In the private sector, several small pharmaceutical companies now focus on drugs for rare diseases, and some large companies are expressing increased interest in the incentives for orphan drug development.

Why Dublin?

A ‘rare disease’ is defined in Europe as a life-threatening or chronically debilitating disease affecting no more than 5 people per 10,000. There are an estimated 6-8,000 known rare diseases affecting up to 6% of the total EU population, (at least 30 million Europeans), and perhaps up to 300,000 Irish people during their lives. Dublin, Ireland has had considerable input into the research section of the Rare Diseases Research, as part of our efforts to ensure that this aspect to organise a conference on rare diseases and Orphan Drugs treatment. it is recognised that accurate and timely diagnosis and access to treatment for individuals with rare diseases are severely hampered by a few major issues. These include lack of recognition and visibility in health care systems leading to difficulties in coordination and communication, the lack of national policies with limited and fragmented resources for individuals with rare diseases, with often the lack of specific clinical expertise for the condition in Dublin. This Rare Diseases conference brought together rare disease researchers from across the country to focus on strengths and weaknesses of rare disease research and to shape the plan for the future.

Members Associated with Rare Diseases and Orphan Drugs Research

The aim of the Rare Diseases conference in Health Care initiative is to assist in reducing dissemination of infections associated with the Rare Diseases, by assisting with the assessment, planning, implementation and diagnostic procedures and treatment strategies for Rare Diseases and Orphan Drugs procedures. The ultimate goal is to endorse quality promotion of health care which is safe for patients, health care workers, others in the health care setting and the environment, in the Rare Diseases Research

Major Research Associations Related to Rare Diseases and Orphan Drugs

Alzheimer's disease Organizations

Ann & Robert H. Lurie Children’s Hospital

Birmingham children’s Hospital

Boston Children’s Hospital

Canadian Organization for Rare Diseases

Chicago Rare Disease Foundation

Children’s hospital of Pittsburgh

Comer Children’s Hospital – University of Chicago

Cystic Fibrosis Foundation

European Union Committee of Experts on Rare Diseases

EURORDIS Rare Diseases Europe

EveryLife Foundation for Rare Diseases

Global Genes Allies in Rare Diseases

Guardian Hands Foundation

Hospitals Associated with Rare Diseases Research

IRDR Intractable & Rare Diseases Research

Japan Patient Association

Multiple Myeloma Research Foundation

National Alliances for Rare Diseases

National Institute of Health (NIH)

National Organization for Rare Diseases

NDC Medicine

Organization for Rare Diseases India (ORDI)

Orphan Europe

Philippine Society for Orphan Disorders

Rare Disease UK

Rare Diseases or Syndromes and Clinical Societies

Rare Diseases Foundation, Iran

Rare Diseases Patient Association Funding

Rare Diseases South Africa

Rare Diseases Translational Research Collaboration

Rare Disorders Society Singapore

RARE Foundation Alliance

Royal Society of Medicine

Short Bowel Syndrome Foundation


The Asia-Pacific Alliance of Rare Disease Organisations

The Boler-Parseghian Center for Rare & Neglected Diseases

The Boler-Parseghian Center for Rare & Neglected Diseases

The Children’s Hospital of Philadelphia

The Every Life Foundation for Rare Diseases

The Genetic and Rare Disorders Organization

The Greek Alliance for Rare Diseases

The Manton Center for Orphan Disease Research

U.S. Food and Drug Administration

UCLA Health

US hospital for Rare Disease Research

Major Universities Associated with Rare Diseases Research

Anahuac University North Campus, Mexico

Australian National University, Australia

Benha University, Egypt

Birmingham City University, UK

Center for Clinical Pharmacology, Belgium

Center for Rare Neurological Diseases, USA

Charles Darwin University Casoria Australia

Columbia University Medical Center, United States

Columbia University, USA

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Duke University, USA

Emory University, USA

GMEC, The Global Medical Excellence Cluster

Guangzhou Medical University, China

Harvard University, United States

Harvard University, USA

Imperial College London, United Kingdom

Infection Control University

Iqbal Chest Centre, Bangladesh

John Hopkins University, USA

Johns Hopkins University, United States

Karolinska University, Sweden

Kindai University, Japan

King Saud Bin Abdulaziz University, Saudi Arabia

King's College London, UK

Kumamoto University, Japan

Linnaeus University, Sweden

Macquarie University, Australia

Mayo Clinic College of Medicine, USA

McGill university   Montréal, Canada

McMaster University, Canada

Medi7 Bentleigh, Australia

Murdoch University   Murdoch, Australia

National Institutes of Health, USA

Newcastle University, Australia

Northwestern University, Qatar

Osaka University, Japan

Oxford University, UK

Philip Morris International R&D, Switzerland

Pompeu Fabra University, Spain

Queen Mary University, UK

Radboud University Medical Center, Netherlands

Rare Genomics Institute, USA

Research Institute of Hospital del Mar, Spain

Rizzoli Orthopedic Institute, Italy

Samsung Medical Center, South Korea

St George’s University of London, UK

St. George Hospital, Australia

Stanford University, USA

Tasmanian Health Service, Australia

The Chest & Heart Association of Bangladesh, Bangladesh

The Fourth Hospital of Harbin Medical University, China

The Jikei University School of Medicine, Japan

The Third Affiliated Hospital of Guangzhou Medical University, China

The University of Newcastle, Australia

Tufts university, United States

United Hospital, Bangladesh

University College London, UK

University of British Columbia, Canada

University of Buffalo, United States

University of California Los Angeles, United States

University of California, USA

University of Cambridge, USA

University of Canberra Bruce, Australia

University of Celiac Disease Center, USA

University of Chicago Medicine, USA

University of Colorado, USA

University of Groningen, Netherlands

University of Lincoln, UK

University of London Imperial College of Science Technology And Medicine, UK

University of Maastricht, Netherlands

University of Maryland Medical Center, Australia

University of Maryland Medical Center, United States

University of Melbourne, Australia

University of Minnesota, United States

University of Newcastle, Australia

University of Pennsylvania, USA

University of Pittsburgh Study

University of Pittsburgh, USA

University of Queensland, Australia

University of Tasmania, Australia

University of Toronto, Canada

University of Valencia, Spain

University of Washington, USA

University of Zurich, Switzerland

University-of-the-sunshine-coast, Australia

Weill Cornell Medical College, Qatar

Wits University, South Africa

Yale University School of Medicine, USA

Yonsei University, South Korea

Major Companies Associated with Rare Diseases and Orphan Drugs

700thespians Limited, UK

Abbott Laboratories, UK

Actavis, USA

Aegerion Pharmaceuticals, Japan

Alexion Pharmaceuticals Inc, Switzerland

Almirall, Spain

Amgen, USA

Amicus Therapeutics, USA

Amphastar Pharmaceuticals, Inc

Araim Pharmaceuticals

Astellas Pharma US

AstraZeneca, Switzerland

AstraZeneca, UK

Baxter International Deerfield

Bayer HealthCare, Germany

Bayer, Germany

Beacon Pharmaceuticals, Bangladesh

Biotie Therapies Corp, Finland

Bioxyne Limited, Australia

Boehringer Ingelheim, Germany

Celgene, Switzerland

Centrapharm Ltd, UK

Chiesi Pharmaceutical, Italy

Clalit Health Service, Israel

Cohero Health, USA

Daiichi Sankyo Europe, Germany

Daiichi Sankyo, Japan

Dohmen Life Science

Elma Reseach, UK

European Medicines Agency

Focus Scientific Research Center (FSRC), phamax, India

Forest Laboratories, USA

Gecko Health, USA

Generics (UK) Ltd, UK

Genus Oncology Vernon Hills, USA

Genzyme, USA

Gilead sciences, USA

GlaxoSmithKline, UK

Global Data, UK

Gsk, London

Hormosan Pharma, Germany

Hormosan Pharma, Germany

Ikris Pharma Network Pvt Ltd, India

Ikris Pharma Network Pvt Ltd, India

Kissei Pharmaceutical Co., Ltd, Japan

Kyowa Hakko Kirin Co. Ltd, Japan

Lallemand Pharma, Switzerland

Life Arc, UK

Marathon Pharmaceuticals

Merck & Co, USA

Millennium Pharmaceuticals

Napp Pharmaceuticals Ltd, UK

Novartis, Switzerland

NPS Pharmaceuticals

Octapharma, USA

Onyx Pharmaceuticals, USA

Otsuka Holdings Co., Ltd, Japan

Panmira Pharmaceuticals, LLC, USA

Pearl Therapeutics, Inc

Pfizer, USA

PharmaMar, USA

Prosensa, Netherlands

PT Boehringer Ingelheim, Indonesia

Queensland Respiratory Laboratory Pty. Ltd, Australia

Ranbaxy Laboratories Limited

Raptor Therapeutics

Roche, Switzerland

Samsung Medical Center, South Korea

Sanofi, France

Sarepta Therapeutics, USA

Sigma-Tau Pharmaceuticals, Italy

Sunovion Pharmaceuticals, USA

Swedish Orphan Biovitrum AB, Sweden

Takeda, Japan

TriStem Corp Ltd, UK

Vertex Pharmaceuticals, USA


ViroPharma, USA

Visionary Pharmaceuticals, Inc, USA

Yungjin Pharm Ind. Co., Ltd, South Korea

Market Research on Rare Diseases and Orphan Drugs

Orphan drugs are the stepchildren of the pharmaceutical industry. These medicinal products that are used primarily for the prevention or treatment of life-threatening or debilitating rare diseases have restricted markets and thus limited profitability. Researchers found that of the 86 orphan drugs included in the study, 25 were blockbusters 29 percent of orphan drugs have annual sales greater than $1 billion. This is comparable to 83 out of the 291 non-orphan drugs that were considered to be blockbusters. The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing and more. As a consequence, the pharmaceutical industry has little interest in developing and marketing these drugs which are intended for patients who suffer from rare conditions.

Past Conference Report

Rare Diseases Congress 2017

Rare Diseases Congress-2017 Past Conference Report

With the overwhelming success of the previous conference, Conference Series LLC hosted 2nd World Congress on Rare Diseases and Orphan Drugs during June 29-30, 2017 in London, UK. The conference was marked with the attendance of Editorial Board Members of supported Conference Series LLC journals, scientists, young and brilliant researchers, business delegates and talented student communities representing more than 20 countries, who made this conference fruitful and productive. This conference was based on the theme, “Novel Approaches to Explore the Emerging Insights in the Rare Diseases Research”. 

Rare Diseases Congress 2017 covered the following scientific sessions and discussions:

·         Pediatric Rare Diseases

·         Therapies for Rare Diseases

·         Other Rare Diseases

·         Current Research on Rare Diseases

·         Rare Diseases of Immune System

·         Genetic Diseases and Disorders

·         Rare Hereditary Diseases

·         Rare Ophthalmological Diseases

·         Genetic Diseases and Disorders

·         Strategies for Diagnosis & Treatment

·         Undiagnosed Rare Diseases


We are thankful to our Honourable Guests for their generous support and suggestions:

·         Danilo A Tagle, National Institutes of Health, USA

·         Stefano Giacomini, Rizzoli Orthopaedic Institute, Italy


The conference proceedings were carried out through various scientific-sessions and plenary lectures, of which the following topics were highlighted as Keynote presentations:

·         “Innovative tools for drug development and disease modeling” given by Danilo A Tagle, National Institutes of Health, USA

·      “Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection” delivered by Abdulaziz Aldawood, King Saud Bin Abdulaziz University, Saudi Arabia

·      “Neurofibromatosis and spinal deformities: The severity in pediatric age and treatment” delivered by Stefano Giacomini, Rizzoli Orthopedic Institute, Italy


Various sessions were chaired and co-chaired by:

·         Nadia Ameen, Yale University School of Medicine, USA

·         Wei Zheng, National Institutes of Health, USA

·         Patrick J Tighe, University of Nottingham, UK

·         Danilo A Tagle, National Institutes of Health, USA

Conference Series LLC has taken the privilege of felicitating Rare Diseases Congress-2017 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this event. The esteemed guests, keynote speakers, well-known researchers and delegates shared their innovative research and vast experience through their fabulous presentations at the podium of grand Rare Diseases Congress-2017. We are glad to inform that all accepted abstracts for the conference have been published in Conference Series LLC Journal of Genetic Syndromes & Gene Therapy as a special issue.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support and assistance. With the unique feedback from the event, Conference Series LLC would like to announce the commencement of the “4th World Congress on Rare Diseases and Orphan Drugs” to be held during June 11-12, 2018 in Dublin, Ireland.

Let us meet again @ Rare Diseases Congress-2018

For more information please visit:


Past Reports  Proceedings  Gallery  

Supported By

Journal of Genetic Syndromes & Gene Therapy Journal of Clinical Infectious Diseases & Practice Journal of Clinical Trials Journal of Neuroinfectious Diseases

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by

Past Affiliations

Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos

What People Say....

Thank you for inviting me to this meeting. I enjoyed it very much, and look forward to participating in future meetings


Nadia Ameen
Yale University School of Medicine

I had great time during my talk.Especially, many questions from floor were Very scientific and helpful. Thank you very much again


Jong Wook Chang
Samsung Medical Center
South Korea

On Behalf of me and Dr. Shmuel Prints we thank you for all the help and cooporation at the congess.


Yana Prints, NDC Medicine

Thanks for every things, I will appreciated to see you in next congress soon


Farhang Tohidi
Rare Disease Foundation of Iran